Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract
出版年份 2019 全文链接
标题
Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract
作者
关键词
-
出版物
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-07-29
DOI
10.1002/hed.25891
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma
- (2019) Vatche Tchekmedyian et al. JOURNAL OF CLINICAL ONCOLOGY
- Salivary levels and immunohistochemical expression of selected angiogenic factors in benign and malignant parotid gland tumours
- (2018) Katarzyna Błochowiak et al. Clinical Oral Investigations
- Expression of VEGF₁₆₅b, VEGFR1, VEGFR2 and CD34 in benign and malignant tumors of parotid glands
- (2018) Katarzyna Błochowiak et al. Advances in Clinical and Experimental Medicine
- Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aereodigestive tract (NCT02860936).
- (2018) Laura Locati et al. JOURNAL OF CLINICAL ONCOLOGY
- Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors
- (2017) Renata Ferrarotto et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?
- (2017) Salvatore Alfieri et al. ORAL ONCOLOGY
- What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma
- (2016) A. L. Ho et al. ANNALS OF ONCOLOGY
- A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact
- (2016) L.D. Locati et al. EUROPEAN JOURNAL OF CANCER
- Malignant Salivary Gland Tumors
- (2016) Eric R. Carlson JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- Vascular endothelial growth factor immunoexpression is increased in malignant salivary gland tumors
- (2015) Felipe Paiva Fonseca et al. Annals of Diagnostic Pathology
- Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck
- (2013) David J. Thomson et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
- (2010) Scott A Laurie et al. LANCET ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Survival from salivary glands adenoid cystic carcinoma in European populations
- (2008) Laura Ciccolallo et al. ORAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now